BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25449296)

  • 1. LRIG1 improves chemosensitivity through inhibition of BCL-2 and MnSOD in glioblastoma.
    Ding J; Liu B; He Y; Yuan X; Tian D; Ji B; Wang L; Wu L; Dong H; Wang J; Zhu X; Cai Q; Zhang S; Chen Q
    Cell Biochem Biophys; 2015 Jan; 71(1):27-33. PubMed ID: 25449296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
    Qi XC; Xie DJ; Yan QF; Wang YR; Zhu YX; Qian C; Yang SX
    Biochem Biophys Res Commun; 2013 Aug; 437(4):565-72. PubMed ID: 23850692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
    Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
    Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRIG1 enhances chemosensitivity by modulating BCL-2 expression and receptor tyrosine kinase signaling in glioma cells.
    Guo Z; Chen Q; Liu B; Tian D; Zhang S; Li M
    Yonsei Med J; 2014 Sep; 55(5):1196-205. PubMed ID: 25048475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
    Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
    Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpressed miR-183 promoted glioblastoma radioresistance via down-regulating LRIG1.
    Fan H; Yuan R; Cheng S; Xiong K; Zhu X; Zhang Y
    Biomed Pharmacother; 2018 Jan; 97():1554-1563. PubMed ID: 29793318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRIG1 enhances the radiosensitivity of radioresistant human glioblastoma U251 cells via attenuation of the EGFR/Akt signaling pathway.
    Yang JA; Liu BH; Shao LM; Guo ZT; Yang Q; Wu LQ; Ji BW; Zhu XN; Zhang SQ; Li CJ; Chen QX
    Int J Clin Exp Pathol; 2015; 8(4):3580-90. PubMed ID: 26097540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
    Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
    Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2.
    Xiao Q; Tan Y; Guo Y; Yang H; Mao F; Xie R; Wang B; Lei T; Guo D
    PLoS One; 2014; 9(10):e111419. PubMed ID: 25353163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
    Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
    Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the association between miR‑181b, Bcl‑2 and LRIG1 in oral verrucous carcinoma.
    Deng ZY; Wang YH; Quan HZ; Liu OS; Li YP; Li Y; Zhu W; Munnee K; Tang ZG
    Mol Med Rep; 2016 Oct; 14(4):2991-6. PubMed ID: 27509922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRIG1 enhances cisplatin sensitivity of glioma cell lines.
    Wang X; Xiao Q; Xing X; Tian C; Zhang H; Ye F; Wan F; Wang B; Guo D; Lei T
    Oncol Res; 2012; 20(5-6):205-11. PubMed ID: 23581227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resveratrol inhibits glioma cell growth via targeting LRIG1.
    Liu L; Zhang Y; Zhu K; Song L; Tao M; Huang P; Pan Y
    J BUON; 2018; 23(2):403-409. PubMed ID: 29745084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
    Pyrko P; Schönthal AH; Hofman FM; Chen TC; Lee AS
    Cancer Res; 2007 Oct; 67(20):9809-16. PubMed ID: 17942911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway.
    Chen PM; Cheng YW; Wu TC; Chen CY; Lee H
    Free Radic Biol Med; 2015 Feb; 79():127-37. PubMed ID: 25499851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for LRIG1 in the regulation of malignant glioma aggressiveness.
    Mao F; Wang B; Xiao Q; Xi G; Sun W; Zhang H; Ye F; Wan F; Guo D; Lei T; Chen X
    Int J Oncol; 2013 Mar; 42(3):1081-7. PubMed ID: 23337938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro.
    Wang B; Han L; Chen R; Cai M; Han F; Lei T; Guo D
    Cancer Biol Ther; 2009 Jun; 8(11):1018-23. PubMed ID: 19421009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
    Shi L; Chen J; Yang J; Pan T; Zhang S; Wang Z
    Brain Res; 2010 Sep; 1352():255-64. PubMed ID: 20633539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
    She X; Yu Z; Cui Y; Lei Q; Wang Z; Xu G; Xiang J; Wu M; Li G
    Oncol Rep; 2014 Sep; 32(3):957-64. PubMed ID: 25017996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.